CEMIP细胞迁移诱导和透明质酸结合蛋白在多种癌症中过度表达，并与癌症患者的预后有关。我们在此进行了一项荟萃分析，以探索CEMIP在癌症患者中的预后影响。在四个数据库中系统地搜索了相关已发表的研究。使用合并风险比（HR）、奇数比（OR）和95%置信区间（95% CI）评估CEMIP的作用。使用癌症基因组图谱（TCGA）研究了CEMIP在各种癌症中的预后价值。本荟萃分析包括了11篇文献和1355名患者。结果显示，CEMIP的过度表达显著与不良OS（HR = 3.03；95% CI：2.00-4.59；p＜0.001）、DFS（HR = 3.38；95% CI：2.41-4.74；p＜0.001）相关。提高的CEMIP表达与晚期临床分期、淋巴结转移和差的组织学分级相关。此外，TCGA数据集用于验证CEMIP在多种癌症中高度表达，并与更差的生存率相关。结果表明CEMIP可能是癌症患者的一种新型预后生物标志物。然而，由于包括的研究主要关注亚洲人群，因此需要进一步的研究来验证其适用性。

Cell migration-inducing and hyaluronan-binding protein (CEMIP) is overexpressed in several cancers and is related to prognosis in cancer patients. Here, we conducted a meta-analysis to explore the prognostic effects of CEMIP in cancer patients.Relevant published studies were systematically searched in four databases. The role of CEMIP was evaluated using pooled hazard ratios (HRs), odd ratios (ORs), and 95% confidence intervals (95% CIs). The Cancer Genome Atlas (TCGA) was used to investigate the prognostic value of CEMIP in various cancers.11 literatures with 1355 patients were included in this meta-analysis. The results showed that overexpression of CEMIP was significantly associated with poor OS (HR = 3.03; 95% CI: 2.00-4.59; p < 0.001), DFS (HR = 3.38; 95% CI: 2.41-4.74; p < 0.001). Elevated CEMIP expression is associated with advanced clinical stage, lymph node metastasis, and poor histological grade. In addition, TCGA datasets were used to verify that CEMIP was found highly expressed in multiple cancers and was associated with poorer survival.The results demonstrated that CEMIP could be a novel prognostic biomarker for cancer patients. However, because the included studies mainly focused on Asian populations, further research is needed to verify its applicability.